Phase I study of nab-paclitaxel and gemcitabine chemoradiotherapy for borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma
Not Applicable
- Conditions
- pancreatic cancer
- Registration Number
- JPRN-UMIN000030551
- Lead Sponsor
- Mie university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with allergy for nab-paclitaxel and gemcitabine 2) Patients with severe infection 3) Patients who are considered to be inappropriate for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method existence of DLT
- Secondary Outcome Measures
Name Time Method resection rate, overall survival, progression free survival, safety, histological effect